Loss of bad or bmf accelerates c-myc–induced lymphomagenesis. (A) Tumor-free survival of Eμ-myc (n = 29; median survival, 138 days), Eμ-myc/bad^+/− (n = 47; median survival, 100 days), Eμ-myc/bad^−/− (n = 29; median survival, 78 days), and Eμ-myc/bim^+/− (n = 32; median survival, 67 days). Lymphomas occurred significantly earlier in Eμ-myc/bad^−/− than in wt Eμ-myc animals (P < .001). (B) Tumor-free survival of Eμ-myc, Eμ-myc/bmf^+/− (n = 30; median survival, 100 days), Eμ-myc/bmf^−/− (n = 30; median survival, 87 days), and Eμ-myc/bim^+/−. Lymphomas occurred significantly earlier in Eμ-myc/bmf^+/− (P < .05) and Eμ-myc/bmf^−/− (P < .01) than in wt Eμ-myc animals. (C) Tumor -free survival of Eμ-myc/bad^−/−bmf^+/+, Eμ-myc/bad^−/−bmf^+/− (n = 16), and Eμ-myc/bad^−/−bmf^−/−mice (n = 11). (D) Distributions of pro/pre-B (light gray), mixed (dark gray), IgM⁺ (black), and B220⁺CD4⁺ (white) lymphomas occurring in mice of the indicated genotypes. The distribution of lymphoma phenotypes was significantly different in Eμ-myc/bmf^−/− compared with Eμ-myc animals (P < .01, χ² test). (E) Kaplan-Meier analysis of IgM⁺ and mixed lymphomas (top) and of pre-B lymphomas (bottom) of Eμ-myc (black solid line), Eμ-myc/bad^+/− (light gray, dashed line), Eμ-myc/bad^−/− (light gray, solid line), Eμ-myc/bmf^+/− (dark gray dotted line), and Eμ-myc/bmf^−/− (dark gray solid line) mice. IgM⁺ B lymphomas arose significantly earlier in Eμ-myc/bmf^−/− (P < .001) and Eμ-myc/bad^−/− (P < .01) than in wt Eμ-myc mice. Pre-B lymphomas were not significantly accelerated by loss of either bad or bmf.